The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
- 1 September 1999
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 128 (2) , 403-411
- https://doi.org/10.1038/sj.bjp.0702807
Abstract
1 The kinetics and nature of equilibrium binding were used to characterize the molecular interaction of the anthranilic acid derivative [3H]-XR9576 with the multidrug resistance P-glycoprotein (P-gp). XR9576 displayed specific high-affinity binding to P-gp (Bmax = 275 pmol mg-1, Kd = 5.1 nM). The transport substrates [3H]-vinblastine and [3H]-paclitaxel displayed 4 fold and 20 fold lower affinity respectively for P-gp. The duration of action of XR9576 with P-gp was increased in comparison to that of vinblastine which displayed a slower rate of association and a faster dissociation rate. 2 The relative affinities of several modulators and transport substrates to interact with P-gp were determined from displacement drug equilibrium binding assays. Vinblastine and paclitaxel could only fractionally displace [3H]-XR9576 binding, displaying Ki values significantly different from their measured Kd values. This suggests a non-competitive interaction between XR9576 and the P-gp substrates vinblastine and paclitaxel. 3 XR9576 was shown to be a potent modulator of P-gp mediated [3H]-vinblastine and [3H]-paclitaxel transport as it increased the steady-state accumulation of these cytotoxics in CHrB30 cells to levels observed in non-P-gp-expressing AuxB1 cells (EC50 = 487+/-50 nM). This inhibition of drug transport is not mediated through competition for transport since [3H]-XR9576 accumulation was not influenced by P-gp expression or function. 4 These results demonstrate that the P-gp modulator XR9576 exhibits greater selectivity, duration of inhibition and potency of interaction with this transporter than any other reported modulators. Several lines of evidence suggest that XR9576 inhibits P-gp function by binding at a site which is distinct from the site of interaction of transport substrates. The two sites may be classified as serving modulatory or transport functions.Keywords
This publication has 31 references indexed in Scilit:
- The multi‐drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P‐glycoprotein by an allosteric interactionBritish Journal of Pharmacology, 1997
- Mutually co-operative interactions between modulators of P-glycoproteinBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1997
- Antagonist inhibition curves and the measurement of dissociation constantsBritish Journal of Pharmacology, 1997
- Saturable Function of P-Glycoprotein as a Drug-efflux Pump in Multidrug-resistant Tumour CellsJournal of Pharmacy and Pharmacology, 1996
- Co-operative, competitive and non-competitive interactions between modulators of P-glycoproteinBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1996
- Functional Modulation of Multidrug Resistance-related P-glycoprotein by Ca2+-CalmodulinJournal of Biological Chemistry, 1995
- Characterization of the ATPase Activity of Purified Chinese Hamster P-glycoproteinBiochemistry, 1994
- The multidrug‐resistance‐reverser verapamil interferes with cellular P‐glycoprotein‐mediated pumping of daunorubicin as a non‐competing substrateEuropean Journal of Biochemistry, 1994
- P-glycoprotein possesses A 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding siteBiochemical and Biophysical Research Communications, 1992
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973